Oncomine Focus assay panel and Oncomine Knowledgebase Reporter.
|
|
- Kathlyn Norman
- 6 years ago
- Views:
Transcription
1 Oncomine Focus assay panel and Oncomine Knowledgebase Reporter. How it can help to identify relevant alteration and early phase trials. Dr Isabelle SOUBEYRAN Dr Emmanuel KHALIFA Molecular Pathology Unit Institut Bergonié France ESMO THERMO FISHER SCIENTIFIC SYMPOSIUM
2 NGS panel for testing mutations, copy number variations and RNA alterations OKR to process NGS data and link it to trials Our experience
3 MAIN TYPES OF MOLECULAR ALTERATION TO BE SCREENED MICROLESIONS SINGLE NUCLEOTIDE VARIANT COPY NUMBER VARIANT (CNV) MACROLESIONS FUSION GENES EML4 ALK
4 Conventional approach Microtome FISH Fusion Genes qpcr Nucleic Acid Extraction CGH CNV Copy Number Variation Sanger SNV Single Nucleotide Variation
5 NGS approach FISH Fusion Genes Nucleic Acid Extraction qpcr NGS CGH Copy Number variant Sanger Single Nucleotide Variant
6 52 unique genes 269 amplicons in DNA panel, 271 amplicons in RNA panel Oncomine Focus Assay Hotspot genes, n=35 Copy Number Variants, n=19 Fusion drivers, n=23 AKT1 ALK AR BRAF CDK4 CTNNB1 DDR2 EGFR ERBB2 ERBB3 ERBB4 ESR1 FGFR2 FGFR3 GNA11 GNAQ HRAS IDH1 IDH2 JAK1 JAK2 JAK3 KIT KRAS MAP2K1 MAP2K2 MET MTOR NRAS PDGFRA PIK3CA RAF1 RET ROS1 SMO DNA Panel ALK AR BRAF CCND1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 KIT KRAS MET MYC MYCN PDGFRA PIK3CA ALK RET ROS1 NTRK1 NTRK2 NTRK3 FGFR1 FGFR2 FGFR3 MET BRAF RAF1 ERG ETV1 ETV4 ETV5 ABL1 AKT3 AXL EGFR ERBB2 PDGFRA PPARG Thermo Fisher All Rights Reserved For Research Use Only. Not for use in diagnostic procedures. RNA Panel
7 COPY NUMBER VARIATION DETECTION 19 genes Detection threshold : At least 4 copies At least 10 amplicons involved ALK AR BRAF CCND1 CDK4 CDK6 EGFR ERBB2 FGFR1 FGFR2 FGFR3 FGFR4 KIT KRAS MET MYC MYCN PDGFRA PIK3CA Ref. genes Chromosome APC 5 BIRC2 11 BRCA1 17 DCUN1D1 3 MED12 X NF1 17 *For Research Use Only. Not for use in diagnostic procedures. Depth ratio: tumoral DNA/Bioinformatic baseline (48 XY patients) Normalisation with reference genes Gender information+++ Tumoral cellularity+++
8 ALK RET ROS1 NTRK1 NTRK2 NTRK3 FGFR1 FGFR2 FGFR3 MET BRAF RAF1 ERG ETV1 ETV4 ETV5 ABL1 AKT3 AXL EGFR ERBB2 PDGFRA PPARG Gene A FUSION TRANSCRIPTS DETECTION: PRINCIPLES (AMPLISEQ STRATEGY) 1- DIRECT DETECTION OF 269 KNOWN TARGETED FUSION BREACKPOINTS Gene B primer 5 a Amplicon AB primer 3 b Driver oncogene 2- IMBALANCE ASSAY PRINCIPLE Fusion partner (ALK, ROS1, RET and NTRK1) Fusion breakpoint Expression 5' Expression 3' Oncogène driver Partenaire de fusion Imbalance expression between the 5' assay and the 3' assay of the driver gene Possibility to identify new fusion transcripts between genes included in the RNA panel primer 5 a Gene A Gene D primer 3 d 5 3 Oncogenic Fusion Reciprocal Fusion Transcript Transcript ' expression 3' expression Driver oncogene Fusion partner Confirmation for the fusion calls Improve sensitivity by providing indirect evidence of a fusion other than those targeted by the panel *For Research Use Only. Not for use in diagnostic procedures.
9 Relative representation of the 23 driver oncogenes in Oncomine Focus Fusion panel 25.0 ALK RET ROS1 NTRK NTRK2 NTRK3 FGFR1 FGFR FGFR3 MET BRAF RAF ERG ETV1 ETV4 ETV5 5.0 ABL1 AKT3 AXL ERBB2 0.0 PDGFRA PPARG *For Research Use Only. Not for use in diagnostic procedures.
10 Relative histotype representation in Oncomine Focus Fusion panel N = nb FT in histotype 269 FT Oncomine Fusion panel optimized for NSCLC, CNS and thyroid tumor testing *For Research Use Only. Not for use in diagnostic procedures.
11 Oncomine Knowledge Base Reporter Efficient and intuitive tool for screening clinical trials Updated several times a year Allows to filter according to type of cancer, gene and trials *For Research Use Only. Not for use in diagnostic procedures.
12 Option 1 : Automatic interpretation of predefined variants with OVAT Tumoral sample information entry TORRENT SUITE SERVER Raw data Annotated vcf SNV detection Bam files ION REPORTER CNV detection RNA alteration detection OVAT Selection of predefined pathogenic variants (Thermofisher database) Oncomine Knowledge Base Reporter Edition of clinical trials available
13 Option 2 : Manual interpretation of pathogenicity by the biologist Tumoral sample information entry TORRENT SUITE SERVER Raw data Annotated vcf SNV detection Bam files ION REPORTER CNV detection RNA alteration detection Biological interpretation OVAT and validation of variants Evaluation of pathogenicity Selection of predefined pathogenic variants (Thermofisher database) Oncomine Knowledge Base Reporter Edition of clinical trials available
14 Oncomine Knowledge Base Reporter Functions and settings Allows to upload variant file filtered by OVAT (automatic interpretation) Allows to interrogate relevance of gene alteration (manual interpretation) Option tools to filter trials according to country/center availability Thermo Fisher All Rights Reserved For Research Use Only. Not for use in diagnostic procedures.
15 OKR Example of Met alteration Administrations approvals Trials available Thermo Fisher All Rights Reserved For Research Use Only. Not for use in diagnostic procedures.
16 Clinical trial description Thermo Fisher All Rights Reserved For Research Use Only. Not for use in diagnostic procedures.
17 GLOBAL ANALYSIS IN THE CONTEXT OF BIP PROTOCOL AT BERGONIE INSTITUTE (about the 300 first samples screened by Oncomine Focus assay)
18 BERGONIE INSTITUTE PROFILING (BIP) Goal : Identify relevant molecular alterations in cancer research High throughput analysis : NGS Oncomine Focus assay Inclusion criteria : Solid malignant tumor or hematological malignancy Advanced disease Performance status < 2 Measurable disease according to RECIST 1.1 TRIAL TYPE PROMOTOR TARGETS DRUG NAMES MOST Umbrella Centre Léon Bérard AcSé Crizotinib AcSé Vemurafénib Basket ABL1, KIT, PDGFRA/B, DDR1/2, CSF1R PIK3CA, PIK3R1, AKT12, mtor, TSC1/2, PTEN VEGFR1-3, PDGFRB, FLT3, BRAF (non V600), CRAF, KRAS, RET ERBB2 VEGFR1-3, PDGFRA/B, KIT ALK1, ROS1, MET Nilotinib Everolimus Sorafenib Lapatinib Pazopanib Crizotinib Unicancer Basket BRAF Vemurafénib STRTRK-2 Basket IGNYTA Inc NTRK1-3, ALK1, ROS1 Entrectinib LOXO-101 Basket LOXO Oncology NTRK1-3 Larotrectinib KIDES Basket Orion FGFR1-4, VEGFR1-3 ODM203 JNJ Basket Janssen RD FGFR1-4 Erdafitinib BET Basket GSK Ampli N-MYC GSK MEDIOLA Basket AstraZeneca BRCA / PDL1 MEDI Olaparib GSK Basket GlaxoSmithKline BRAF Dabrafenib
19 Repartition of histological types in our series(%) tumor types representing 52% of the samples
20 DESCRIPTIVE ANALYSIS of ALTERATIONS AND GLOBAL YIELD IN BIP PROTOCOL 50 0 % Oncomine focus assay global yield All Somatic alterations Novel somatic alterations Actionable alterations Alteration types distribution 23% 4% Mutations 73% Amplifications RNA alterations Patient (%)
21 Tumor recruitment versus Histotype fusion panel representation Panel under-exploited for thyroid and CNS fusion detection in our series
22 COMPARATIVE YIELD OF RELEVANT ALTERATIONS: BY TUMORAL TYPE Yield by tumoral type (all somatic alterations) NSCLC CERVIX COLORECTAL ENDOMETRIAL GASTRIC OVARIAN PANCREAS SARCOMA BREAST UROTHELIAL Histotype recruitment (%) Histotype contribution to global yield (%)
23 COMPARATIVE YIELD OF RELEVANT ALTERATIONS: PRIMARY VERSUS METASTATIC SITES Number of samples screened Number of samples with at least one actionable alteration 0 Primary site Metastatic site
24 Is CGH-array has additional value to Oncomine Focus assay to screen tumors? /82 cases : - PTEN homoz del - AKT2/VEGFA amp - AR amp - BRCA2 homoz del All tumor sequenced Complementary CGH Actionable Targets detected by CGH Conclusion : In our series, CGH-array yields up only few additional relevant alteration when no new targetable alteration is detected by Oncomine Focus panel *For Research Use Only. Not for use in diagnostic procedures.
25 COMPARATIVE YIELD OF ACTIONABLE ALTERATIONS: ONCOMINEFOCUS ASSAY VERSUS 426 GENES PANEL 426 genes panel (568 tumors) Oncomine focus assay (52 genes) on 300 tumors Tumors screened: n=300 Tumors with at least one relevant alteration: n=136 (37,6%) *For Research Use Only. Not for use in diagnostic procedures.
26 Take home messages Globally Oncomine focus panel yield allows to identify > 37% of tumors with at least 1 actionable alteration The RNA panel is optimized for non epidermoid NSCLC theranostic screening Under-exploitment of panel in our series Screening yield in a trial depends on panel volume as number of potential drugs available Oncomine Knowledge base Reporter is an efficient and intuitive tool for screening clinical trials
27 THANKS Molecular Pathology Lab Dr Emmanuel Khalifa Dr Benjamin Bonhomme Félix Lefort Magali Philips Isabelle Hostein Gaelle Pérot Jennifer Chiron Mathilde Beunardeau Céline Auzanneau Larry Blanchard Mélanie Muller Laetitia Nègre-Mayeur Agnès Ribeiro Marie-Cécile Blard Marlène Boucheix Nathalie Mérillon-Tortevoie Charlotte Primois Léa Ries Ghislaine Sierankowski
28 Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties during this seminar. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.
SureSelect Cancer All-In-One Custom and Catalog NGS Assays
SureSelect Cancer All-In-One Custom and Catalog NGS Assays Detect all cancer-relevant variants in a single SureSelect assay SNV Indel TL SNV Indel TL Single DNA input Single AIO assay Single data analysis
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationTargeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
More informationThe linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine
The linking of specific cancer genetic alterations to molecular targeted therapies is driving a new era of personalised medicine Oncologica addresses this new era of precision medicine by exploiting state
More informationDr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester
Dr David Guttery Senior PDRA Dept. of Cancer Studies and CRUK Leicester Centre University of Leicester dsg6@le.ac.uk CFDNA/CTDNA Circulating-free AS A LIQUID DNA BIOPSY (cfdna) Tumour Biopsy Liquid Biopsy
More informationNext Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
More informationIMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY
Madrid, Spain IMPLEMENTING NEXT GENERATION SEQUENCING IN A PATHOLOGY LABORATORY Dr. JL Rodríguez Peralto NGS Ion Torrent Oncomine Focus Assay - Implementation experience for EGFR mutation detection
More informationPersonalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
More informationFluxion Biosciences and Swift Biosciences Somatic variant detection from liquid biopsy samples using targeted NGS
APPLICATION NOTE Fluxion Biosciences and Swift Biosciences OVERVIEW This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationJennifer Hauenstein Oncology Cytogenetics Emory University Hospital Atlanta, GA
Comparison of Genomic Coverage using Affymetrix OncoScan Array and Illumina TruSight Tumor 170 NGS Panel for Detection of Copy Number Abnormalities in Clinical GBM Specimens Jennifer Hauenstein Oncology
More informationGenomic Medicine: What every pathologist needs to know
Genomic Medicine: What every pathologist needs to know Stephen P. Ethier, Ph.D. Professor, Department of Pathology and Laboratory Medicine, MUSC Director, MUSC Center for Genomic Medicine Genomics and
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More informationIllumina s Cancer Research Portfolio and Dedicated Workflows
Illumina s Cancer Research Portfolio and Dedicated Workflows Michael Sohn Clinical Sales Specialist Spain&Italy 2017 2017 Illumina, Inc. All rights reserved. Illumina, 24sure, BaseSpace, BeadArray, BlueFish,
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationClinical Grade Genomic Profiling: The Time Has Come
Clinical Grade Genomic Profiling: The Time Has Come Gary Palmer, MD, JD, MBA, MPH Senior Vice President, Medical Affairs Foundation Medicine, Inc. Oct. 22, 2013 1 Why We Are Here A Shared Vision At Foundation
More informationWhat is the status of the technologies of "precision medicine?
Session 2: What is the status of the technologies of "precision medicine? Gideon Blumenthal, MD, Clinical Team Leader, Thoracic and Head/Neck Oncology, Center for Drug Evaluation and Research (CDER), U.S.
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More information5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff
5 th July 2016 ACGS Dr Michelle Wood Laboratory Genetics, Cardiff National molecular screening of patients with lung cancer for a national trial of multiple novel agents. 2000 NSCLC patients/year (late
More informationEXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationDiagnostica Molecolare!
Diagnostica Molecolare! Aldo Scarpa Unità Diagnostica Molecolare Azienda Ospedaliera Universitaria Integrata di Verona e ARC-NET Centro di Ricerca Applicata sul Cancro PDTA CARCINOMA POLMONARE - IL PAZIENTE
More informationClick to edit Master /tle style
Click to edit Master /tle style Tel: (314) 747-7337 Toll Free: (866) 450-7697 Fax: (314) 747-7336 Email: gps@wustl.edu Website: gps.wustl.edu GENETIC TESTING IN CANCER Ka/nka Vigh-Conrad, PhD Genomics
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Oncofocus Patient Test Report Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL www.oncologica.com - Tel: +44 (0)1223 785327
More informationThe Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
More informationClinical Grade Biomarkers in the Genomic Era Observations & Challenges
Clinical Grade Biomarkers in the Genomic Era Observations & Challenges IOM Committee on Policy Issues in the Clinical Development & Use of Biomarkers for Molecularly Targeted Therapies March 31-April 1,
More informationOut-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationKarl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
Expanding on WHO guideline compliant molecular testing of central nervous system tumors by low density whole genome sequencing. Karl Kashofer, Phd Institut für Pathologie Medizinische Universität Graz
More informationSecuenciación masiva: papel en la toma de decisiones
Secuenciación masiva: papel en la toma de decisiones Cancer is a Genetic Disease Development of cancer is driven by the acquisition of somatic genetic alterations: Nonsynonymous point mutations: missense.
More informationSelect analysis on the next pages. Sample request and sending address see last page. Institut für Pathologie und Molekularpathologie
Diagnostic Tumor Genome Analysis Schmelzbergstrasse 12 8091 Zürich Tel.: (+41) 044 255 3929 Fax.: (+41) 044 255 4416 Client (address, telephone number): ngs.pathologie@usz.ch www.pathologie.usz.ch Sample-Nr:
More informationWebinar Series. Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels. Participating experts
Characterizing cancers from liquid biopsies and FFPE samples: The rise of targeted sequencing panels April 13, 2016 Webinar Series Brought to you by the Science/ AAAS Custom Publishing Office Participating
More informationRNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) Tissue Enabling Next Generation Detection of Gene Fusions
RNA Extraction from Formalin Fixed Paraffin Embedded (FFPE) Tissue Enabling Next Generation Detection of Gene Fusions William M. Rehrauer, PhD Associate Professor University of Wisconsin School of Medicine
More informationImplementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges
Implementation of nation-wide molecular testing in oncology in the French Health care system : quality assurance issues & challenges Frédérique Nowak - 21 october 2015 "Putting Science into Standards event:
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationIllumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
More informationTargeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders
Targeted Molecular Diagnostics for Targeted Therapies in Hematological Disorders Richard D. Press, MD, PhD Dept of Pathology Knight Cancer Institute Knight Diagnostic Labs Oregon Health & Science University
More informationComprehensive Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Genomic Profiling, in record time Accurate. ly Proven. Fast. PCDx advantages Comprehensive genomic profiling, in record time PCDx Comprehensive Genomic Profiling (CGP) provides precise information
More informationClinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD
Clinically Useful Next Generation Sequencing and Molecular Testing in Gliomas MacLean P. Nasrallah, MD PhD Neuropathology Fellow Division of Neuropathology Center for Personalized Diagnosis (CPD) Glial
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Panel Testing of Cancers to Identify Targeted Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_panel_testing_of_cancers_to_identify_targeted_therapies
More informationProtein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies
Protein Domain-Centric Approach to Study Cancer Somatic Mutations from High-throughput Sequencing Studies Dr. Maricel G. Kann Assistant Professor Dept of Biological Sciences UMBC 2 The term protein domain
More informationFusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas
Fusion Analysis of Solid Tumors Reveals Novel Rearrangements in Breast Carcinomas Igor Astsaturov Philip Ellis Jeff Swensen Zoran Gatalica David Arguello Sandeep Reddy Wafik El-Deiry Disclaimers Dr. Igor
More informationAVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits
AVENIO family of NGS oncology assays ctdna and Tumor Tissue Analysis Kits Accelerating clinical research Next-generation sequencing (NGS) has the ability to interrogate many different genes and detect
More informationOncology Drug Development
Oncology Drug Development Advantages and challenges of using stratified clinical studies Simon J Hollingsworth The 18th Anti-Tumour Drug Development Forum 21 February Japan Stratified Medicine In The Clinic
More informationDetecting Oncogenic Mutations in Whole Blood
WHITE PAPER Detecting Oncogenic Mutations in Whole Blood Analytical validation of Cynvenio Biosystems LiquidBiopsy circulating tumor cell (CTC) capture and next-generation sequencing (NGS) September 2013
More informationWhat is Precision Medicine?
Precision Medicine and the Treatment of Cancer Carlos L. Arteaga, MD Center for Cancer Targeted Therapies VICC Breast Cancer Program Vanderbilt-Ingram Cancer Center (VICC) Departments of Medicine and Cancer
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationAugust 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
More informationEnabling Personalized
Molecular Enabling Personalized Diagnostics Medicine- Targeted Sequencing: NGS-based solutions Silvia Dorn Roel Reinders- Andreas Diplas Friday, 19.06.2015 Company Overview Founded in April 2011 Development
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationIdentification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins
Identification and clinical detection of genetic alterations of pre-neoplastic lesions Time for the PML ome? David Sidransky MD Johns Hopkins February 3-5, 2016 Lansdowne Resort, Leesburg, VA Molecular
More informationExpanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD
Expanding Therapeutic Options for Cancer Patients with Comprehensive Profiling Alexander Drilon MD Clinical Director, Early Drug Development Service Memorial Sloan Kettering Cancer Center COI Disclosure
More informationPatricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope
Patricia Aoun MD, MPH Professor and Vice-Chair for Clinical Affairs Medical Director, Clinical Laboratories Department of Pathology City of Hope National Medical Center Disclosures I have no disclosures
More informationGenomic tests to personalize therapy of metastatic breast cancers. Fabrice ANDRE Gustave Roussy Villejuif, France
Genomic tests to personalize therapy of metastatic breast cancers Fabrice ANDRE Gustave Roussy Villejuif, France Future application of genomics: Understand the biology at the individual scale Patients
More informationMEDICAL POLICY. SUBJECT: MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES (Excluding NSCLC and CRC) EFFECTIVE DATE: 12/21/17
MEDICAL POLICY SUBJECT: MOLECULAR PANEL TESTING OF PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationAVENIO ctdna Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB
Analysis Kits The complete NGS liquid biopsy solution EMPOWER YOUR LAB Analysis Kits Next-generation performance in liquid biopsies 2 Accelerating clinical research From liquid biopsy to next-generation
More informationNext Generation Sequencing: What Will it Mean for the Pathologist?
Next Generation Sequencing: What Will it Mean for the Pathologist? Christopher Corless, MD, PhD Professor of Pathology, Oregon Health & Science University Chief Medical Officer, Knight Diagnostic Laboratories
More informationMolecular Aspects of Melanocytic Neoplasia. Iwei Yeh MD, PhD University of California, San Francisco
Molecular Aspects of Melanocytic Neoplasia Iwei Yeh MD, PhD University of California, San Francisco Thanks to: Boris Bastian Timothy McCalmont Philip LeBoit Beth Ruben Jeff North Laura Pincus Thaddeus
More informationNext-generation sequencing based clinical testing for lung cancer in Japan
Review Article Next-generation sequencing based clinical testing for lung cancer in Japan Masayuki Takeda 1, Kazuko Sakai 2, Kazuhiko Nakagawa 1, Kazuto Nishio 2 1 Department of Medical Oncology, 2 Department
More informationNext generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
More informationPlasma-Seq conducted with blood from male individuals without cancer.
Supplementary Figures Supplementary Figure 1 Plasma-Seq conducted with blood from male individuals without cancer. Copy number patterns established from plasma samples of male individuals without cancer
More informationThe NCI- MATCH (EAY131) Precision Medicine Trial: Lessons Learned and Status Update
The NCI- MATCH (EAY131) Precision Medicine Trial: Lessons Learned and Status Update Robert L. Comis, MD Oslo Cancer Cluster Cancer Crosslinks 2016 October 19, 2016 1 1 NCI-Molecular Analysis for Therapy
More informationMédecine de précision en oncologie
Médecine de précision en oncologie Académie Nationale de Pharmacie Mercredi 3 octobre 2018 Antoine Hollebecque, MD Département d Innovation Thérapeutique et Essais précoces (DITEP) Gustave Roussy Precision
More informationTumor mutational burden and its transition towards the clinic
Tumor mutational burden and its transition towards the clinic G C C A T C A C Wolfram Jochum Institute of Pathology Kantonsspital St.Gallen CH-9007 St.Gallen wolfram.jochum@kssg.ch 30th European Congress
More informationImplementation of BRCA Oncomine panel for germline and somatic variant analysis
Tagliafico ESHG 2017.pptm 3.2% 03/03/2017 Implementation of BRCA Oncomine panel for germline and somatic variant analysis Enrico Tagliafico MD, PhD, Modena, Italy Center for Genome Research University
More informationNSCLC 2 nd and further line therapies. Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute
NSCLC 2 nd and further line therapies Egbert F. Smit MD PhD. Dept. Thoracic Oncology, Netherlands Cancer Institute e.smit@nki.nl ESMO Guidelines 2016: Treatment of Stage IV nonsquamous NSCLC at progression
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationDevelopments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA
Developments in small cell lung cancer G. Giaccone, MD PhD Chief, Medical Oncology Branch and Affiliates National Cancer Institute Bethesda MD USA Geneva April 20, 2012 Neuroendocrine tumors of lung Typical
More informationMEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers
POLICY: PG0067 ORIGINAL EFFECTIVE: 07/30/02 LAST REVIEW: 01/25/18 MEDICAL POLICY Genetic Testing for Breast and Ovarian Cancers GUIDELINES This policy does not certify benefits or authorization of benefits,
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationSOMATIC MUTATION FREQUENCIES MONITORING
CANCER PRODROMAL STAGE ASSESSMENT SOMATIC MUTATION FREQUENCIES MONITORING PREVENTION PROGRAM spin off SOLID CANCER PRODROMAL STAGE ASSESSMENT By yearly monitoring the occurrence of cancerassociated mutations
More informationNew Drug development and Personalized Therapy in The Era of Molecular Medicine
New Drug development and Personalized Therapy in The Era of Molecular Medicine Ramesh K. Ramanathan MD Virginia G. Piper Cancer Center Translational Genomics Research Institute Scottsdale, AZ Clinical
More informationMolecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationCancer Gene Panels. Dr. Andreas Scherer. Dr. Andreas Scherer President and CEO Golden Helix, Inc. Twitter: andreasscherer
Cancer Gene Panels Dr. Andreas Scherer Dr. Andreas Scherer President and CEO Golden Helix, Inc. scherer@goldenhelix.com Twitter: andreasscherer About Golden Helix - Founded in 1998 - Main outside investor:
More informationSALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.
SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationNGS ONCOPANELS: FDA S PERSPECTIVE
NGS ONCOPANELS: FDA S PERSPECTIVE CBA Workshop: Biomarker and Application in Drug Development August 11, 2018 Rockville, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration
More informationMolecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.
Molecular Oncology & Pathology Hereditary Cancer Somatic Cancer Liquid Biopsy Next-Gen Sequencing qpcr Sanger Sequencing Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationTumor Gene Sequencing: Ready for a Revolution?
Tumor Gene Sequencing: Ready for a Revolution? Philippe Aftimos, M.D. Clinical Pharmacology Unit Institut Jules Bordet Brussels, Belgium ICBD Antwerp February 7 th, 2015 IHC: Historical Biomarkers Cold
More informationNeoTYPE Cancer Profiles
NeoTYPE Cancer Profiles 30+ Multimethod Assays for Hematologic Diseases and Solid Tumors Molecular FISH Anatomic Pathology The next generation of diagnostic, prognostic, and therapeutic assessment What
More informationNGS IN ONCOLOGY: FDA S PERSPECTIVE
NGS IN ONCOLOGY: FDA S PERSPECTIVE ASQ Biomed/Biotech SIG Event April 26, 2018 Gaithersburg, MD You Li, Ph.D. Division of Molecular Genetics and Pathology Food and Drug Administration (FDA) Center for
More informationThe oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC
The oncologist s point of view: the promise and challenges of increasing options for targeted therapies in NSCLC Egbert F. Smit Department of Thoracic Oncology, Netherlands Cancer Institute, and Department
More informationThe mutations that drive cancer. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge
The mutations that drive cancer Paul Edwards Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge Previously on Cancer... hereditary predisposition Normal Cell Slightly
More informationThe Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
More informationPathologists role Ancillary Studies in Cytology Challenges. Pre-analytical issues. LUNG CYTOLOGY Predictive markers and molecular tests
Pathologists role LUNG CYTOLOGY Predictive markers and molecular tests Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Pathology Unit, IPATIMUP
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationPractical Implications of Next Generation Sequencing (NGS) in Breast Cancer: Promises and Challenges
Practical Implications of Next Generation Sequencing (NGS) in Breast Cancer: Promises and Challenges Naoto T. Ueno, MD, PhD, FACP Professor of Medicine Executive Director, Morgan Welch Inflammatory Breast
More informationMulti-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer
Multi-drug, genetic-marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer Sponsor: University of Birmingham Chief Investigator: Gary Middleton Chief Biostatistician:
More informationA 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper)
A 10-year summary of kinase small molecule research Text mining AACR abstracts (white paper) Approved Kinase Inhibitors September 2014 Sponsored by PamGene www.pamgene.com The Kinase Activity Profiling
More informationChanging the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle
Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center
More informationpatients in the era of
Communicating with cancer patients in the era of personalized medicine September 9 th, 2017 Gerald Prager, M.D. Comprehensive Cancer Center Vienna Medical University of Vienna, Austria Gerald Prager, M.D.
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationExpanded Molecular Panel Testing of Cancers to Identify Targeted Therapies
Expanded Molecular Panel Testing of Cancers to Identify Targeted Therapies Policy Number: Original Effective Date: MM.02.028 10/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationCopy number and somatic mutations drive tumors
Detection of copy number alterations, ploidy and loss of heterozygosity across the genome in FFPE specimens Utility for diagnosis and treatment with comparison to FISH-based and as a complement to sequencing
More informationRegulatory Landscape for Precision Medicine
Regulatory Landscape for Precision Medicine Adam C. Berger, Ph.D. Office of In Vitro Diagnostics and Radiological Health, FDA FOCR-Alexandria A Blueprint for Breakthrough Meeting September 13, 2017 1 What
More information